Skip to main content
Iranian Journal of Basic Medical Sciences logoLink to Iranian Journal of Basic Medical Sciences
. 2017 Aug;20(8):849–855. doi: 10.22038/IJBMS.2017.9105

Frequency of bap and cpaA virulence genes in drug resistant clinical isolates of Acinetobacter baumannii and their role in biofilm formation

Arezoo Fallah 1,2, Mohammad Ahangarzadeh Rezaee 1,3,*, Alka Hasani 3, Mohammad Hossein Soroush Barhaghi 4, Hossein Samadi Kafil 5
PMCID: PMC5651469  PMID: 29085575

Abstract

Objective(s):

Acinetobacter baumannii has a high propensity to form biofilm and frequently causes medical device-related infections with multiple-drug-resistance in hospitals. The aim of this work is to study antimicrobial resistance and the role of bap and cpaA genes in biofilm formation by A. baumannii to understand how this pathogen persists in the hospital environment.

Materials and Methods:

The antibiotic resistance profile and in vitro biofilm-forming ability of one hundred clinical isolates of A. baumannii was evaluated by disc diffusion and crystal-violet staining methods, respectively. Isolates were tested for the presence of bap and cpaA genes.

Results:

The isolates were highly resistant to cefepime, third-generation cephalosporins, ciprofloxacin, cotrimoxazole, aminoglycosides and carbapenems. Moreover, four isolates were resistant to colistin. Quantification of biofilm showed that 43% of the isolates were strong biofilm-producer. Furthermore, 32% of the isolates exhibited moderate biofilm-formation and showed initial binding activity. Frequency of bap and cpaA were determined 92% and 36%, respectively.

Conclusion:

There was strong association between the presence of bap gene and biofilm formation by A. baumannii isolates (P=0.003). In addition, multidrug resistant isolates produced stronger biofilm than other isolates (P=0.0001). These results indicate importance of biofilm in resistance of isolates and effect of presence of bap gene in biofilm formation by A. baumannii strains.

Keywords: Acinetobacter baumannii, Antibiotic resistance, Biofilm, Bap, CpaA

Introduction

The growing prevalence of multi- or pan-drug resistant Acinetobacter baumannii strains has resulted in limited treatment choices. Most of A. baumannii strains are resistant to clinically valuable antibiotics (1), with inferable deaths up to 43% for patients under intensive care and 23% for hospitalized patients (2). In fact, biofilm production is another effective route for bacteria to survive in the presence of antibiotics (3), particularly for A. baumannii that causes biofilm-related contamination of medical devices (4).

Given the implications that biofilm formation has in medical care, isolation of bacterial species form biofilms and detection of the genetic determinants to control this complex procedure became an active field of research over the last few years. Biofilms are a dynamic, highly structured heterogeneous commu-nities of bacteria inside a polymeric conglomerate of polysaccharides and proteins that have integrated metabolic activities and create sessile phenotypes markedly different from their planktonic partners (5, 6). Bacterial biofilms have been found on surfaces of plastic, glass and numerous sorts of medical devices as well as on a kind of other surfaces in the hospital environment (7). Biofilms are resistant to antibiotics, detergents and host immune defenses, and antibiotic resistance of microorganisms in these colonies can be increased up to 1000-fold (3).

As in different pathogens, a substantial protein expressed at the A. baumannii cell surface, known as biofilm-associated protein (Bap), has a role in biofilm production as in host cell adherence (8). Bap family members are characterized as high-molecular weight proteins that are available on the bacterial surface, contain a core domain of tandem repeats, and give to bacteria the ability to form a biofilm (9). Since

the initial identification of Bap, its homologue counterparts have been recognized in at least 13 pathogenic species, and the proteins commonly share functional and structural similarities, although not necessarily primary sequence similarity (9, 10). Bap production has been linked to primary adherence to abiotic surfaces, biofilm formation in both Gram-positive and Gram-negative bacteria, persistence and subsequent pathogenesis (11). The A. baumannii Bap protein is important for stabilization of mature biofilms on glass, influencing both biovolume and thickness (12). This information recommends that A. baumannii Bap is a key factor in biofilm production and therefore may have a role in persistence in the hospital environment and in infection.

A. baumannii bacteremia regularly originates in the respiratory tract and moves to the circulatory system where it is associated with very high mortality rates due at least in part to disseminated intravascular coagulation (DIC) or septic shock (13). Patients suffering from A. baumannii infections have been appeared to have unusual coagulation-related proteins (14), which are basic to antimicrobial defense (15, 16) and a target of various Gram-negative virulence factors (17). Here, we investigate CpaA (coagulation targeting metallo-endopeptidase of A. baumannii), a novel reprolysin-like secreted metallo-endopeptidase, present in clinical isolates. To our knowledge, few studies have examined association between cpaA gene and the coagulation as a means of A. baumannii virulence. Therefore, we chose to study biofilm formation by A. baumannii and the prevalence of bap and cpaA genes in order to understand how this pathogen persists in the hospital environment to cause outbreaks worldwide.

Materials and Methods

Sample collection

A total of 100 A. baumannii isolates from different clinical sources were collected from three referral University affiliated health-care centers (Imam Reza, Sina, and Children) in Tabriz, Iran during May 2015 to July 2016 (14 month time period). These isolates were isolated from urine, wound, blood, bronchial secretion, pharynx, bile and tracheal aspirates. All presumptive Acinetobacter spp. isolates, which were Gram-negative diplococci, non-lactose fermentative and oxidase-negative, were identified as A. baumannii by utilizing the conventional methods and growth potential at 37 °C and 44 °C (18). Later, polymerase chain reaction (PCR) amplification was performed to confirm species identification using the intrinsic blaoxa-51-like allele as described previously (19). Finally, genomic DNA of the isolates was extracted as described previously (20).

Ethics standards

Ethics approval to perform the study was obtained from the institutional review board of Tabriz University of Medical Sciences. Written informed consent was obtained from all patients included in the study.

Antimicrobial susceptibility testing

Kirby-Bauer disk diffusion methods was perform-ed to determine antimicrobial susceptibility patterns in accordance with the recommendations of the clinical and laboratory standards institute (CLSI) (21). The tested antimicrobial agents that were purchased from Hi-media, India were as follow: ciprofloxacin (30 µg), imipenem (10 µg), meropenem (10 µg), gentamicin (10 µg), cotrimoxazole (25 µg), amikacin (30 µg), ceftazidime (30 µg), cefotaxime (30 µg), amikacin (30 μg), cefepime (30 μg), tetracycline (10 µg), and colistin (10 µg). Escherichia coli ATCC 25922 was used as a quality control strain. Multidrug resistance (MDR) was characterized as resistance of an isolate to three or more unrelated antimicrobial agents (22). Resistance to one drug class was regarded as resistance to all antimicrobial members of that class.

Biofilm formation assay

A. baumannii biofilm formation was analyzed in 96-well flat bottom polystyrene plates, under static conditions for 48 hr as previously described (23, 24). For biofilm development, inoculums of around 107 CFU/ml were prepared by adjusting culture grown bacterial suspensions in trypticase soy broth (TSB) (Hi-media, India) from overnight cultures to an optical density (OD600 nm) of 0.1 and adding 100 μl of every inoculums to wells. After 48 hr incubation, plates were tenderly washed one time with 1X phosphate buffered saline (PBS; pH 7.4) and stained with 100 μl of 0.1% Crystal Violet (CV) for 30 min at room temperature. Excess CV was expelled by washing, and biofilm was evaluated by measuring absorbance of the supernatant at 570 nm utilizing a microtiter plate reader after the solubilization of CV in 95% ethanol. Biofilm assays were performed in triplicate for each clinical strain and the mean biofilm absorbance quality was determined.

bap and cpaA gene detection

The specific primers for the bap gene (Bap-F, 5′ TAG GGA GGG TAC CAA TGC AG and Bap-R, 5′ TCA TGA TTT GAT GCT GCA GCG ATA A) and the cpaA gene (CpaA-F, 5′ CTG CTT TAG GAA AAT GGG and CpaA-R, 5′ CGC CTT CAA TCA TTC TAA G) were used to evaluate the biofilm formation (17, 25). The bap gene was amplified under the following conditions: 95 °C for two min, 95 °C for 30 sec, 61 °C for 30 sec, 68 °C for one min (30 cycles), and 68 °C for two min. Also, PCR condition for cpaA gene was as follow: 95 °C for three min, 95 °C for 30 sec, 63 °C for 30 sec, 72 °C for one min (35 cycles), and 68 °C for five min. The PCR products were separate in 1.5% agarose gel.

Statistical methods

All statistics have been evaluated by means of SPSS software version 22.0 (SPSS Inc, Chicago, IL, USA). Comparative data was calculated utilizing the Fisher’s exact and two-tailed χ2 test, once appropriate. A P-value of ≤ 0.05 was thought to be significant.

Results

Descriptive epidemiology

In the present study, 100 non-duplicative A. baumannii was isolated from different clinical specimens, including tracheal aspirates (50%), wound (15%), urine (13%), blood (12%), pharynx (5%), bronchial secretion (4%), and bile aspirates (1%). The A. baumannii isolates were collected from different wards of the three referral and University affiliated hospitals includes Imam Reza (51%), Sina (38%), and Children (11%) centers. The most clinical isolates were obtained from intensive care units (56%) and other isolates were obtained from other wards such as, burn, lung, internal, surgery, kidney, neurology and trauma, respectively. The mean age of the patients was 49±24 years and the ratio between genders was 1:0.8 (males/females). Of the isolates identified as Acinetobacter spp. phenotypically, all confirmed as A. baumannii by using OXA-51-like primers and observing ~ 353 bp band in the agarose gel.

Antimicrobial susceptibility testing

Resistance to cefepime was the most common (99%), followed by cefotaxime and ceftazidime (97%), imipenem (92%), ciprofloxacin (91%), cotrimoxazole (74%), amikacin (60%), meropenem (52%), gentamicin (51%), tetracycline (48%), and colistin (4%) (Figure 1). Antibiotic susceptibility profiles of A. baumannii isolates according to the different specimen from the hospitalized patients were shown in Table 1. About 90% of the isolates were resistant to at least one of the tested carbapenems antibiotics, which included imipenem and meropenem. No isolate was resistant to all of the 11 antibiotics. Of the 100 A. baumannii isolates tested, all were resistant to at least one antibiotic. Additionally, 88 isolates were classified as MDR.

Figure 1.

Figure 1

Antibiotic susceptibility of the Acinetobacter baumannii isolates

Abbreviations; MRP, meropenem; AN, amikacin; IMP, imipenem; CL, colistin; CAZ, ceftazidime; GEN, gentamicin; SXT, cotrimoxazole; CP, ciprofloxacin; CTX, cefotaxime; TE, tetracycline; CPM, cefepime. Numbers depicted in the above figure present susceptibility as percentage of bacterial isolates. Mueller-Hinton agar was used for susceptibility test. The inoculum concentration was 1.5 × 108

Table 1.

Antibiotic resistance patterns of Acinetobacter baumannii isolates according to various specimens

Specimen CP IMP MRP GEN SXT AN CAZ CTX CPM TE CL
Tracheal aspirates 45 46 23 22 39 26 48 49 49 23 3
Urine 12 11 5 5 10 8 13 13 14 6 0
Wound 14 13 10 8 10 8 14 14 14 7 0
Blood 10 12 8 7 8 9 12 11 12 7 1
Bronchial secretion 4 4 2 3 2 3 4 4 4 1 0
Pharynx 5 5 3 5 4 5 5 5 5 3 0
Bile 1 1 1 1 1 1 1 1 1 1 0
Total 91 92 52 51 74 60 97 97 99 47 4

MRP: meropenem; AN: amikacin; IMP, imipenem; CL, colistin; CAZ, ceftazidime; GEN, gentamicin; SXT, cotrimoxazole; CP, ciprofloxacin; CTX, cefotaxime; TE, tetracycline; CPM, cefepime

Biofilm formation

Evaluation of biofilm formation by microtiter plate method presented 43% (n=43) of the isolates as strong biofilm producer; moreover, these isolates had stronger initial attachment capacity to microtiter wells. About 32% (n=32) displayed moderate biofilm formation, which indicated moderate initial binding activity, while weak or no biofilm was observed in 25% (n=25) of the isolates.

Presence of bap and cpaA genes

All isolates involved in this study possessed one of the A. baumannii bap and/or the cpaA genes.

Ninety-two (92%) isolates in the study possessed the A. baumannii bap gene and 36 (36%) possessed the cpaA gene. Of the isolates that had bap, 64 possessed it alone and the other 28 ones had the combination of bap and cpaA. The percentage of virulence gene detected in A. baumannii strains according to the site of isolation was shown in Table 2. Furthermore, the relation between presence of each virulence genes and biofilm formation are presented in Table 3.

Table 2.

The percentage of virulence genes detected in Acinetobacter baumannii strains according to the site of isolation

Genes Tracheal aspirates Urine Wound Blood Bronchial secretion Pharynx Bile Total
bap Positive 45 12 13 11 5 5 1 92
Negative 5 1 1 1 0 0 0 8
cpaA Positive 16 5 3 6 5 1 0 36
Negative 34 8 11 6 0 4 1 64
Total 50 13 14 12 5 5 1 100

Table 3.

Statistical analysis of the relationship between biofilm formation and the presence of bap and cpaA genes in Acinetobacter baumannii strains with multidrug resistance (MDR)

bap cpaA MDR

Positive Negative Positive Negative Positive Negative Total
Biofilm Weak 19 (76.0%) 6 (24.0%) 4 (16.0%) 21 (84.0%) 16 (64.0%) 9 (36.0%) 25
Moderate 32 (100%) 0 (0%) 12 (37.5%) 20 (62.5%) 31 (96.9%) 1 (3.1%) 32
Strong 41 (95.5%) 2 (4.0%) 20 (46.5%) 23 (53.5%) 41 (95.3%) 2 (4.7%) 43
Total 92 (92.0%) 12 (12.0%) 36 (36.0%) 64 (64.0%) 88 (88.0%) 12 (12.0%) 100
P-value 0.003 0.40 0.000

Discussion

A. baumannii is an important nosocomial pathogen that is omnipresent in environment, associated with MDR and hospital outbreaks of infection resulting in high levels of morbidity and mortality, especially in the intensive care units (26, 27). It also accounts for almost 80% of all reported Acinetobacter infections, including bacteremia, urinary tract infections, ventilator-associated pneumonia, peritonitis, wound infections and meningitis (26). These infections have turned into a challenge for clinicians and a real threat to international public health because of the rapid spread of antimicro-bial resistance and the slow development of novel antimicrobials (28). Moreover, the genetic capability of

MDR A. baumannii to carry and transfer diverse anti-biotic resistance determinants represents a noteworthy risk in hospitals. This contributes largely to the lethality and severity of infections, in addition to the high rate of chronic infections, as the organism is able to persist and survive for a long period of time, even after treatment with antibiotics and disinfectants.

In the recent years, the antimicrobial suscepti-bility rates have been highly decreased among A. baumannii isolates in Iran; there are generally more resistance to antibiotics in Iran than those from different regions of the world (29, 30). The current study found 100 isolates of A. baumannii collected from different wards of three main hospitals in Tabriz, Iran, which were highly resistant to different classes of antibiotics, and the prevalence of MDR isolates was 88%. The rate of carbapenems resistance in A. baumannii is also increasing during the past years in our region, and in this study, we found that up to 92% and 60% of isolates were resistant to imipenem and amikacin, respectively. However, the profile of antibiotic resistance shows with the exception of carbapenems, amikacin was relatively the most active antimicrobial agent against most isolates of A. baumannii (with susceptibility rate of 41.5%) (30). According to the data, resistance to colistin in non-fermenters such as A. baumannii is relatively low (28). In our study, 4% of isolates were resistant to this drug. While, in other studies from the North and Northwest of Iran, the rate of 16% and 19% have been reported, respectively (31, 32).

A. baumannii and Pseudomonas aeruginosa are the most common bacteria that form biofilm. In our study, 75% of these A. baumannii clinical isolates exhibited a higher capacity for biofilm formation, and multidrug resistant isolates produced stronger biofilm than other isolates (P=0.000) (Table 3). This attachments as biofilm in microtiter plates contributed to their outstanding antibiotic resistance properties to a wide variety of antibiotics (33). This is a relatively higher rate than that observed in other studies. However, evaluation of biofilm formation by microtiter plate method in another study from Iran showed that among 81% of carbapenem non-susceptible A. baumannii, 52% of the isolates were biofilm producers (34). In Korea, it was reported that all 23 (100%) strains of MDR A. baumannii formed biofilm (35). The results of studies from Spain and the United States showed that 63% (36) and 55% of A. baumannii strains isolated from wounds were biofilm-forming strains, with a median biofilm mass of 0.125±0.061 (37).

Yet, presence and expression of genes associated with biofilm formation ought to be confirmed by genotypic characterization methods. Bap were initially characterized in Staphylococcus aureus (38) and has since been recognized in a number of other Gram-negative and Gram-positive pathogenic bac-teria. They are characterized by functional qualities and shared structural features and are essentially high-molecular-weight, repetitive surface proteins involved in biofilm formation (39). To determine whether Bap expression is involved in biofilm formation on medically relevant surfaces, biofilm studies were performed on polystyrene, polypropylene, and titanium. As shown in Table 3, there was strong association between the presence of bap gene and biofilm formation by A. baumannii isolates (P=0.003) in this study. A recent study has shown that Bap plays a role in static biofilm maturation and maintenance, increasing both biofilm thickness and biovolume on glass surfaces (12). Moreover, in a study that conducted in Iran, the frequency of bap gene related to biofilm formation was 30% (40). However, in our study and another study from Australia (from a single outbreak), 92% of A. baumannii isolates possess this gene (8, 41). As we determined using the CV staining technique, A. baumannii isolates carrying the bap gene and those without bap vary significantly in their biofilm formation capabilities (P<0.05) (Table 3). The biofilm data presented in this study along with other studies confirm that Bap is an extremely important factor in biofilm development and this surface protein is needed in the formation of a classic biofilm phenotype on surfaces. These results are important because the ability of A. baumannii to survive and persist on abiotic materials is linked to outbreaks of nosocomial infections. In order to develop more effective ways of eradicating A. baumannii contamina-tion from the environment, we must identify the bacterial factors that are important for persistence, and our data implicate Bap as a key component.

Various bacterial secreted proteases are known to interact with host systems to promote infection. According to the data, CpaA-treated plasma has reduced clotting activity in contact pathway-activated partial thromboplastin time (aPTT) assays, but increased clotting activity in tissue factor pathway prothrombin time (PT) assays (17). CpaA has limited homology to any other described peptides in regions other than the active site; it was therefore important to determine whether the protease is active, and whether it targets host-derived substrates as a potential virulence mecha-nism. In our study, we detected the secreted protease CpaA of 36 A. baumannii clinical isolate (Table 3); while, in other research, 12/16 (75%) of A. baumannii clinical isolates generated amplicons from primers designed to amplify cpaA gene (17).

Conclusion

To the best of our knowledge, this is the first research to examine the association between cpaA gene and the coagulation as a means of A. baumannii virulence in Iran. This study indicates that the presence of the cpaA gene among A. baumannii isolates is not associated with in vitro formation of biofilm (P>0.05). However, there was strong association between presence of bap gene and biofilm formation by A. baumannii isolates (P=0.003). In addition, multidrug resistant isolates produced stronger biofilm than other isolates (P=0.000). These results indicate importance of biofilm in resistance of isolates and effect of the presence of bap gene in biofilm formation by A. baumannii strains. Moreover, these results recommend the need for further investi-gation involving a large number of multicentric A. baumannii isolates collected from Iran.

Acknowledgment

This work was fully supported by Immunology Research Center (grant No. 94-02), Tabriz University of Medical Sciences, Tabriz, Iran. It is also a report originating from a database developed for the thesis of first author registered in Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. The study was approved by and performed under the guidelines of the research ethics committee of Tabriz University of Medical Sciences. We thank staff of Imam Reza, Children and Sina hospitals for their cooperation.

Conflicts of interest

The authors declare that no conflict of interest exists.

References

  • 1.Durante-Mangoni E, Utili R, Zarrilli R. Combination therapy in severe Acinetobacter baumannii infections:an update on the evidence to date. Future Microbiol. 2014;9:773–789. doi: 10.2217/fmb.14.34. [DOI] [PubMed] [Google Scholar]
  • 2.Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients:a systematic review of matched cohort and case-control studies. Crit Care. 2006;10:R48. doi: 10.1186/cc4869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms:from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95–108. doi: 10.1038/nrmicro821. [DOI] [PubMed] [Google Scholar]
  • 4.Singhai M, Malik A, Shahid M, Malik MA, Goyal R. A study on device-related infections with special reference to biofilm production and antibiotic resistance. J Glob Infect Dis. 2012;4:193. doi: 10.4103/0974-777X.103896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Sutherland IW. The biofilm matrix–an immobilized but dynamic microbial environment. Trends Microbiol. 2001;9:222–227. doi: 10.1016/s0966-842x(01)02012-1. [DOI] [PubMed] [Google Scholar]
  • 6.Stoodley P, Sauer K, Davies D, Costerton JW. Biofilms as complex differentiated communities. Ann Rev Microbiol. 2002;56:187–209. doi: 10.1146/annurev.micro.56.012302.160705. [DOI] [PubMed] [Google Scholar]
  • 7.Patel SJ, Oliveira AP, Zhou JJ, Alba L, Furuya EY, Weisenberg SA, et al. Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units. Am J Infect Control. 2014;42:626–631. doi: 10.1016/j.ajic.2014.01.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Luo TL, Rickard AH, Srinivasan U, Kaye KS, Foxman B. Association of blaOXA-23 and bap with the persistence of Acinetobacter baumannii within a major healthcare system. Front Microbiol. 2015;6:182. doi: 10.3389/fmicb.2015.00182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lasa I, Penadés JR. Bap:a family of surface proteins involved in biofilm formation. Res Microbiol. 2006;157:99–107. doi: 10.1016/j.resmic.2005.11.003. [DOI] [PubMed] [Google Scholar]
  • 10.Latasa C, Solano C, Penadés JR, Lasa I. Biofilm-associated proteins. C R Biol. 2000;329:849–857. doi: 10.1016/j.crvi.2006.07.008. [DOI] [PubMed] [Google Scholar]
  • 11.Brossard KA, Campagnari AA. The Acinetobacter baumannii biofilm-associated protein plays a role in adherence to human epithelial cells. Infect Immun. 2012;80:228–233. doi: 10.1128/IAI.05913-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Loehfelm TW, Luke NR, Campagnari AA. Identification and characterization of an Acinetobacter baumannii biofilm-associated protein. J Bacteriol. 2008;190:1036–1044. doi: 10.1128/JB.01416-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest. 2006;129:102–109. doi: 10.1378/chest.129.1.102. [DOI] [PubMed] [Google Scholar]
  • 14.Soares AJ, Santos M, Trugilho M, Neves-Ferreira A, Perales J, Domont G. Differential proteomics of the plasma of individuals with sepsis caused by Acinetobacter baumannii. J Proteomics. 2009;73:267–278. doi: 10.1016/j.jprot.2009.09.010. [DOI] [PubMed] [Google Scholar]
  • 15.Delvaeye M, Conway EM. Coagulation and innate immune responses:can we view them separately? Blood. 2009;114:2367–2374. doi: 10.1182/blood-2009-05-199208. [DOI] [PubMed] [Google Scholar]
  • 16.Massberg S, Grahl L, von Bruehl M-L, Manukyan D, Pfeiler S, Goosmann C, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010;16:887–896. doi: 10.1038/nm.2184. [DOI] [PubMed] [Google Scholar]
  • 17.Tilley D, Law R, Warren S, Samis JA, Kumar A. CpaA a novel protease from Acinetobacter baumannii clinical isolates deregulates blood coagulation. FEMS Microbiol Lett. 2014;356:53–61. doi: 10.1111/1574-6968.12496. [DOI] [PubMed] [Google Scholar]
  • 18.MacFaddin JF. Biochemical tests for identification of medical bacteria. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000. [Google Scholar]
  • 19.Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27:351–353. doi: 10.1016/j.ijantimicag.2006.01.004. [DOI] [PubMed] [Google Scholar]
  • 20.Pajand O, Ahangarzadeh Rezaee M, Nahaei MR, Mahdian R, Aghazadeh M, Soroush MH, et al. Study of the carbapenem resistance mechanisms in clinical isolates of Acinetobacter baumannii:Comparison of burn and non-burn strains. Burns. 2013;39:1414–1419. doi: 10.1016/j.burns.2013.03.024. [DOI] [PubMed] [Google Scholar]
  • 21.Clinical Laboratory Standards Institute, M100-S24:Performance Standards for Antimicrobial Susceptibility testing:Twenty-First Informational Supplement. Wayne, Pa, USA: Clinical Laboratory Standards Institute; 2014. [Google Scholar]
  • 22.Ahangarzadeh Rezaee M, Abdinia B. Etiology and antimicrobial susceptibility pattern of pathogenic bacteria in children subjected to UTI:A referral hospital-based study in Northwest of Iran. Medicine. 2015;94:e1606. doi: 10.1097/MD.0000000000001606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kafil HS, Mobarez AM, Moghadam M, Hashemi ZMY. Gentamicin induces efaA expression and biofilm formation in Enterococcus faecalis. Microb Pathog. 2016;92:30–35. doi: 10.1016/j.micpath.2015.12.008. [DOI] [PubMed] [Google Scholar]
  • 24.Kafil HS, Mobarez AM. Assessment of biofilm formation by enterococci isolates from urinary tract infections with different virulence profiles. J King Saud Univ-Sci. 2015;27:312–7. [Google Scholar]
  • 25.Akers KS, Mende K, Cheatle KA, Zera WC, Yu X, Beckius ML, et al. Biofilms and persistent wound infections in United States military trauma patients:a case-control analysis. BMC Infect Dis. 2014;14:190. doi: 10.1186/1471-2334-14-190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii:emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538–582. doi: 10.1128/CMR.00058-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Bergogne-Berezin E, Towner K. Acinetobacter spp. as nosocomial pathogens:microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9:148–165. doi: 10.1128/cmr.9.2.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bialvaei AZ, Samadi Kafil H. Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin. 2015;31:707–721. doi: 10.1185/03007995.2015.1018989. [DOI] [PubMed] [Google Scholar]
  • 29.Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001;134:298–314. doi: 10.7326/0003-4819-134-4-200102200-00014. [DOI] [PubMed] [Google Scholar]
  • 30.Soroush S, Haghi-Ashtiani MT, Taheri-Kalani M, Emaneini M, Aligholi M, Sadeghifard N, et al. Antimicrobial resistance of nosocomial strain of Acinetobacter baumannii in Children’s Medical Center of Tehran:a 6-year prospective study. Acta Med Iran. 2010;48:178–184. [PubMed] [Google Scholar]
  • 31.Sohrabi N, Farajnia S, Akhi MT, Nahaei MR, Naghili B, Peymani A, et al. Prevalence of OXA-type β-lactamases among Acinetobacter baumannii isolates from Northwest of Iran. Microb Drug Resist. 2012;18:385–389. doi: 10.1089/mdr.2011.0077. [DOI] [PubMed] [Google Scholar]
  • 32.Ghasemian R, Ahanjan M, Fatehi E, Shokri M. Prevalence and antibiotic resistance pattern of Acinetobacter isolated from patients admitted in ICUs in Mazandaran, Northern Iran. Glob J Health Sci. 2016;8:112–119. [Google Scholar]
  • 33.Mohajeri P, Farahani A, Feizabadi MM, Ketabi H, Abiri R, Najafi F. Antimicrobial susceptibility profiling and genomic diversity of Acinetobacter baumannii isolates:A study in western Iran. Iran J Microbiol. 2013;5:195–202. [PMC free article] [PubMed] [Google Scholar]
  • 34.Azizi O, Shakibaie MR, Modarresi F, Shahcheraghi F. Molecular detection of class-D OXA carbapenemase genes in biofilm and non-biofilm forming clinical isolates of Acinetobacter baumannii. Jundishapur J Microbiol. 2015;8:e21042. doi: 10.5812/jjm.21042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Lee HW, Koh Y, Kim J, Lee JC, Lee YC, Seol SY, et al. Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect. 2008;14:49–54. doi: 10.1111/j.1469-0691.2007.01842.x. [DOI] [PubMed] [Google Scholar]
  • 36.Rodriguez-Bano J, Marti S, Soto S, Fernández-Cuenca F, Cisneros JM, Pachon J, et al. Biofilm formation in Acinetobacter baumannii:associated features and clinical implications. Clin Microbiol Infect. 2008;14:276–278. doi: 10.1111/j.1469-0691.2007.01916.x. [DOI] [PubMed] [Google Scholar]
  • 37.Sánchez CJ, Mende K, Beckius ML, Akers KS, Romano DR, Wenke JC, et al. Biofilm formation by clinical isolates and the implications in chronic infections. BMC Infect Dis. 2013;13:47. doi: 10.1186/1471-2334-13-47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Cucarella C, Solano C, Valle J, Amorena B, Lasa Í, Penadés JR. Bap, a Staphylococcus aureus surface protein involved in biofilm formation. J Bacteriol. 2001;183:2888–2896. doi: 10.1128/JB.183.9.2888-2896.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Lasa I. Towards the identification of the common features of bacterial biofilm development. Intl Microbiol. 2006;9:21–28. [PubMed] [Google Scholar]
  • 40.Badmasti F, Siadat SD, Bouzari S, Ajdary S, Shahcheraghi F. Molecular detection of genes related to biofilm formation in multidrug-resistant Acinetobacter baumannii isolated from clinical settings. J Med Microbiol. 2015;64:538–543. doi: 10.1099/jmm.0.000058. [DOI] [PubMed] [Google Scholar]
  • 41.Goh HS, Beatson SA, Totsika M, Moriel DG, Phan M-D, Szubert J, et al. Molecular analysis of the Acinetobacter baumannii biofilm-associated protein. Appl Environ Microbiol. 2013;79:6535–6543. doi: 10.1128/AEM.01402-13. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Iranian Journal of Basic Medical Sciences are provided here courtesy of Mashhad University of Medical Sciences

RESOURCES